Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valued at $160.7 million. The position now represents 2% of fund assets, making it Armistice's second-largest holding. These 10 stocks could mint the next wave of millionaires › On Friday, New York City-based Armistice Capital disclosed it sold 2,152,000 shares of Travere Therapeutics (NASDAQ:TVTX) in the third quarter, reducing its position by an estimated $29.3 million. What Happened According to a filing with the Securities and Exchange Commission released Friday, Armistice Capital sold nearly 2.2 million shares of Travere Therapeutics during the third quarter. The post-transaction holding stood at 6.7 million shares valued at $160.7 million as of September 30. What Else to Know The fund's sale reduced its Travere Therapeutics stake to 2% of 13F AUM, but the position remains its second-largest holding. Top five holdings after the filing: NASDAQ:PTCT: $201.1 million (6.3% of AUM)
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.MarketBeat
- Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]Seeking Alpha
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TVTX's page on the SEC website